NCT02890212 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Aronson R, Offman HJ, Joffe RT, Naylor CD
Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996 Sep;53(9):842-8. doi: 10.1001/archpsyc.1996.01830090090013.
Ferrier IN
Treatment of major depression: is improvement enough? J Clin Psychiatry. 1999;60 Suppl 6:10-4.
Hawkes WC, Hornbostel L
Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Biol Psychiatry. 1996 Jan 15;39(2):121-8. doi: 10.1016/0006-3223(95)00085-2.
Joffe RT, Levitt AJ
Relationship between antidepressant partial and nonresponse and subsequent response to antidepressant augmentation. J Affect Disord. 1999 Jan-Mar;52(1-3):257-9. doi: 10.1016/s0165-0327(97)00178-x.
McIntyre RS, O'Donovan C
The human cost of not achieving full remission in depression. Can J Psychiatry. 2004 Mar;49(3 Suppl 1):10S-16S.
Rayman MP
The importance of selenium to human health. Lancet. 2000 Jul 15;356(9225):233-41. doi: 10.1016/S0140-6736(00)02490-9.

Double Blind, Placebo Controlled Pilot Study to Evaluate the Use of Selenium as an Augmentation Treatment for Sertraline Resistant Major Depression

Clinical trial NCT02890212 - References